Diaverum, one of the world's leading renal care providers, is planning
to give more patients the possibility to be treated with peritoneal
dialysis to increase their quality of life. Peritoneal dialysis is the
preferred treatment option for patients who either have problems with
vascular access for haemodialysis or have a cardiovascular system not
tolerating haemodialysis. It also offers patients who live far away from
haemodialysis clinics and who prefer to be flexible and independent from
clinic opening hours a good alternative. Currently Diaverum is treating
2 % of its patients with peritoneal dialysis; the target is to increase
this percentage to 7 % by 2015.
Peritoneal dialysis (PD) is a home therapy treatment form for patients
with kidney failure. It uses the patient's peritoneum (http://en.wikipedia.org/wiki/Peritoneum)
(the membrane lining the walls of the abdominal cavity) as a filter
across which newly infused PD fluid acts to remove waste products and
extra fluid accumulated in the blood (http://en.wikipedia.org/wiki/Blood).
"PD can increase quality of life for the patients. They can conduct this
treatment flexibly at home without having to spend four hours in a
dialysis clinic three times a week. By offering a range of different
treatment alternatives for patients with end stage renal disease (ESRD),
such as haemodialysis (HD), PD and kidney transplant, we are giving our
patients the possibility to choose the treatment that best suits their
form of life and their medical condition," commented Dag Andersson, CEO
and President of Diaverum.
"We increased the number of PD treatments by 30 % last year and we are
planning to grow even stronger — particularly in Poland, Hungary and
Argentina where we are seeing a major increase in PD patients."
From a medical point of view, 15-20 % of dialysis patients could be
treated with PD. In reality, the worldwide usage and promotion of PD
varies from country to country. In Hong Kong, for example, 80 % of end
stage renal disease patients are using PD, in Sweden 24 %, in the UK 17
%, while in Austria (9 %), France (7.5 %) and Germany (4.8 %) the
commonness of PD is still very low.
Two key reasons hinder the broader expansion. The first concerns the
lack of knowledge in many markets. Even though PD is a valid alternative
to HD, the vast majority of nephrologists still prefer HD. Studies have
shown that when given unbiased and complete information about both
dialysis alternatives, 50 % of patients would choose PD. In Diaverum it
is a must to inform new patients on the different options of renal
replacement therapy so that they participate in their therapy decision,
as long as no medical contraindication exists for one specific dialysis
modality.
"Increasing the usage of peritoneal dialysis may also reduce the risk of
infection for dialysis patients. The risk of infection and its
complications is lower with PD than with HD using catheters as vascular
access," explained Dr Jose Divino, Vice President Medical Office Home
Therapy at Diaverum.
The second obstacle to the expansion of PD is the different
reimbursement models in the different countries. Moving more patients to
PD may imply a clear financial relief for local health authorities and
payers, since the costs for treating a patient with PD are lower than
treating with HD. Despite this fact, PD is not yet reimbursed in some
countries, but the economic situation in many countries could be a
driving force behind the adoption of PD.